强制降解 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
== Host systems == Genes are subjected to heterologous expression often to study specific protein interactions. E. coli, yeast (S. cerevisiae, P. pastoris), immortalized mammalian cells, and amphibian oocytes (i.e. unfertilized eggs) are commonly for studies that require heterologous expression. In choosing a particular system, economic and qualitative aspects have to be considered. Prokaryotic expression is widely used in recombinant DNA technology to form easily manipulated proteins by well-known genetic methods with a low costing medium. Some limitations include intracellular accumulation of heterologous proteins, improper folding of the peptide, lack of post-transcriptional modifications, the potential for product degradation due to traces of protease impurities, and production of endotoxin. Prokaryotic and eukaryotic systems, most commonly bacteria, yeast, insects, and mammalian cells, and occasionally amphibians, fungi, and protists are used for studies that require heterologous expression. Bacteria, especially E. coli, yeast (S. cerevisiae, P. pastoris), insects, and amphibian (oocyte) cells have been used as effective hosts for expressing foreign proteins. Generally, prokaryotes are easier to work with and better understood and are often the preferable host system. It is widely used in recombinant DNA technology to form easily manipulated proteins by well-known genetic methods with a low costing medium. For membrane proteins though, researchers have observed that mammalian cells are more effective.
There are a number of different psychotherapies for depression which are provided to individuals or groups by psychotherapists, psychiatrists, psychologists, clinical social workers, counselors or psychiatric nurses. With more chronic forms of depression, the most effective treatment is often considered to be a combination of medication and psychotherapy. Psychotherapy is the treatment of choice in people under 18. A meta-analysis examined the effectiveness of psychotherapy for depression across ages from younger than 13 years to older than 75 years. It summarizes results from 366 trials included 36,702 patients. It found that the best results were for young adults, with an average effect size of g=.98 (95% CI, 0.79–1.16). The effects were smallest for young children (<13 years), g = .35 (95% CI, 0.15–0.55), and second largest in the oldest group, g = .97 (95% CI, 0.42–1.52). The study was not able to compare the different types of therapy to each other. Most of the studies with children used therapies originally developed with adults, which may have reduced the effectiveness. The greater benefits with young adults might be due to a large number of studies including college students, who might have an easier time learning therapy skills and techniques. Most of the studies in children were done in the US, whereas in older age groups, more balanced numbers of studies came from Europe and other parts of the world as well.
=== Vince: The Roommate from Hell === First aired: 29 March 2009 Mayhem shows a tape of Josh and Adam, who are bullied by Josh's current and Adam's former roommate Vince, a basketball player. According to Adam, Vince doesn't pay rent, once threw him out of his own house, and broke his door. Vince accepts the challenge to fight, after initially hesitating. In addition to the money, Mayhem adds the additional stipulation that if Vince loses, he has to move out. He shows up to train at Mayhem's gym, during which he falls down after kicking Mayhem's bag, which causes Mayhem to laugh. He shows up to the fight and learns that his opponent will be former NFL wide receiver Michael Westbrook. During the first round, Vince tapped out four times in the first round, and was KO'd in the second round. He apologizes to Adam and Josh after the fight, but says in an interview afterwards that he will not be paying them the back rent, as the $9,000 they have just won will cover it. Adam notes that he will need a new roommate since Vince will be moving out, and asks Josh if he would like to move in with him, which Josh accepts.
=== Continued employment by the Astros === As part of a personal services contract Bagwell signed with the Astros, he served as a coach in spring training of 2007. On July 11, 2010, the Astros hired Bagwell to be their hitting coach, replacing Sean Berry. At the time of the switch, the Astros had the second-worst average (.237) in the majors and the worst OBP (.295). At the end of the season, the team marginally improved, but was still last in the league in OBP (.303) and SLG (.362) and Bagwell announced he would not return as hitting coach. After a five-year gap in contact with the Astros organization, Bagwell accepted a formal invitation from manager A. J. Hinch to be a guest instructor in spring training of 2015. He is currently a special advisor to team owner Jim Crane.
=== Liver Disease === Bhatia's doctoral work laid the foundation for keeping liver cells functional outside the human body. By adapting techniques from computer chip design and photolithography, she microfabricated substrates that support the growth and function of 2D and 3D human liver cells in a lab dish. This led to the invention of the "microliver," a miniature model organ that revolutionized the efficient testing of drug reactions. It is now used globally by companies to evaluate drug efficacy and predict toxic side effects. Further research in her lab, including the use of 3D printing to create synthetic vascular systems, aims to develop larger tissue structures with the ultimate goal of an artificial human liver. This foundational work was among the first at MIT in the area of biological micro-electromechanical systems (Bio-MEMS). The LMRT continues to apply micro- and nanotechnology to tissue repair and regeneration, studying the interactions between hepatocytes (liver cells) and their microenvironment. This work improves cellular therapies for liver disease, maximizes hepatocyte function, and enhances the understanding of liver physiology and pathophysiology. Her research has been instrumental in studying diseases like hepatitis and malaria. In collaboration with Christopher Chen at Boston University, Bhatia's lab developed human microlivers that can be transplanted, vascularized, and survive in vivo, offering potential curative therapies for both heritable and acquired liver diseases.
Sources: en.wikipedia.org
Multiple historic and cultural sites, including UNESCO World Heritage Sites, were damaged. The most affected was Chehel Sotoun and its rich ayeneh-kari. On 2 March, a strike on Arg Square damaged nearby Golestan Palace, prompting UNESCO to issue a statement of concern. On 5 March, the Azadi Sport Complex was bombed. An 8 March strike on Falak-ol-Aflak, which was marked with a blue shield emblem, damaged several sections of the site. Strikes on Isfahan on 9 March damaged Naqsh-e Jahan Square, Chehel Sotoun, Ali Qapu, the Shah Mosque, Jameh Mosque, and Teymouri Hall. On 11 March, UNESCO urged protection for Iran's heritage sites and World Heritage Sites that have been damaged or are under high risk due to the war, alongside other historic sites in Israel, Lebanon, and the rest of West Asia. On 17 March, blast waves and shrapnel damaged multiple palaces at Sa'dabad Complex in northern Tehran. Russia's Ministry of Foreign Affairs reported that strikes in Tehran on 1 April damaged the St. Nicholas Orthodox Church and its auxiliary buildings. On 7 April, the Rafi'-Nia synagogue was fully destroyed by the IAF.
=== Health hazards === Honey is generally safe when taken in typical food amounts, but it may have various, potential adverse effects or interactions in combination with excessive consumption, existing disease conditions, or drugs. Included among these are mild reactions to high intake, such as anxiety, insomnia, or hyperactivity in about 10% of children, according to one study. No symptoms of anxiety, insomnia, or hyperactivity were detected with honey consumption compared to placebo, according to another study. Honey consumption may interact adversely with existing allergies, high blood sugar levels (as in diabetes), or anticoagulants used to control bleeding, among other clinical conditions. People who have a weakened immune system may be at risk of bacterial or fungal infection from eating honey.
=== Qigong === Qigong and Chinese medicine place huge emphasis on a form of energy called 精 (pinyin: jīng, also a morpheme denoting "essence" or "spirit") – which one attempts to develop and accumulate. "Jing" is sexual energy and is considered to dissipate with ejaculation, so masturbation is considered "energy suicide" amongst those who practice this art. According to Qigong theory, energy from many pathways/meridians becomes diverted and transfers itself to the sexual organs during sexual excitement. The ensuing orgasm and ejaculation will then finally expel the energy from the system completely. The Chinese proverb 一滴精，十滴血 (pinyin: yì dī jīng, shí dī xuè, literally: a drop of semen is equal to ten drops of blood) illustrates this point. The scientific term for semen in Chinese is 精液 (pinyin: jīng yè, literally: fluid of essence/jing) and the term for sperm is 精子 (pinyin: jīng zǐ, literally: basic element of essence/jing), two modern terms with classical referents.
internal validation or cross-validation (actually, while extracting data, cross validation is a measure of model robustness, the more a model is robust (higher q2) the less data extraction perturb the original model); external validation by splitting the available data set into training set for model development and prediction set for model predictivity check; blind external validation by application of model on new external data and data randomization or Y-scrambling for verifying the absence of chance correlation between the response and the modeling descriptors. The success of any QSAR model depends on accuracy of the input data, selection of appropriate descriptors and statistical tools, and most importantly validation of the developed model. Validation is the process by which the reliability and relevance of a procedure are established for a specific purpose; for QSAR models validation must be mainly for robustness, prediction performances and applicability domain (AD) of the models. Some validation methodologies can be problematic. For example, leave one-out cross-validation generally leads to an overestimation of predictive capacity. Even with external validation, it is difficult to determine whether the selection of training and test sets was manipulated to maximize the predictive capacity of the model being published. Different aspects of validation of QSAR models that need attention include methods of selection of training set compounds, setting training set size and impact of variable selection for training set models for determining the quality of prediction.
Sources: en.wikipedia.org
=== WISeR Model (AI-assisted prior authorization in Original Medicare) === On January 1, 2026, CMS launched the Wasteful and Inappropriate Service Reduction (WISeR) Model through the Center for Medicare and Medicaid Innovation, introducing prior authorization for selected traditional Medicare Part B services in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. The model uses artificial intelligence to support medical necessity reviews, although all adverse determinations are made by licensed clinicians rather than automated systems. The model drew opposition from the American Hospital Association, which requested a six-month implementation delay, and prompted legislation introduced in late 2025 to repeal it.
The hallmark of linear azol(in)e-containing peptide (LAP) biosynthesis is the formation of azol(in)e heterocycles from the nucleophilic amino acids serine, threonine, or cysteine. This is accomplished by three enzymes referred to as the B, C, and D proteins; the precursor peptide is referred to as the A protein, as in other classes. The C protein is mainly involved in leader peptide recognition and binding and is sometimes called a scaffolding protein. The D protein is an ATP-dependent cyclodehydratase that catalyzes the cyclodehydration reaction, resulting in formation of an azoline ring. This occurs by direct activation of the amide backbone carbonyl with ATP, resulting in stoichiometric ATP consumption. The C and D proteins are occasionally present as a single, fused protein, as is the case for trunkamide biosynthesis. The B protein is a flavin mononucleotide (FMN)-dependent dehydrogenase which oxidizes certain azoline rings into azoles. The B protein is typically referred to as the dehydrogenase; the C and D proteins together form the cyclodehydratase, although the D protein alone performs the cyclodehydration reaction. Early work on microcin B17 adopted a different nomenclature for these proteins, but a recent consensus has been adopted by the field as described above.
== Presence in space == The presence of glycine outside the Earth was confirmed in 2009, based on the analysis of samples that had been taken in 2004 by the NASA spacecraft Stardust from comet Wild 2 and subsequently returned to Earth. Glycine had previously been identified in the Murchison meteorite in 1970. The discovery of glycine in outer space bolstered the hypothesis of so-called soft-panspermia, which claims that the "building blocks" of life are widespread throughout the universe. In 2016, detection of glycine within Comet 67P/Churyumov–Gerasimenko by the Rosetta spacecraft was announced. The detection of glycine outside the Solar System in the interstellar medium has been debated.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.